期刊文献+

伊布利特在控制转复阵发性房颤中的作用研究 被引量:5

Research of ibutilide on cardioversion of paroxysmal atrial fibrillation
下载PDF
导出
摘要 目的比较伊布利特与胺碘酮和普罗帕酮在转复阵发房颤中的疗效及安全性。方法选择阵发性房颤患者90例,随机分成依布利特组(A组)、胺碘酮组(B组)、普罗帕酮组(C组),每组30例。于入院10min内,三组分别经静脉注射依布利特1 mg、胺碘酮150 mg、普罗帕酮70 mg。观察10 min后若仍未转复为窦性心律,重复首次剂量。观察开始给药后1、2、4、24 h内房颤的转复率、转复时间、心室率、QT和QRS间期变化及用药后不良反应的发生情况。结果 A组在各时间点房颤的转复率(83.33%)均显著高于其他组。A组转复时间(24.3±10.7)min明显短于其他组。A组不反应发生率(3.33%)明显低于C组,但与B组比较差异无统计学意义。各组用药后心率均显著降低,A组给药后QT间期较B组和C组显著延长,B组QT间期在用药各时段无明显变化。C组给药后的QRS间期较A组和B组明显延长,A组和B组的QRS间期用药后无明显变化。结论伊布利特对房颤转复的效果优于胺碘酮和普罗帕酮,伊布利特对心室率和QT间期的影响大于胺碘酮和普罗帕酮,但对QRS间期无明显影响。伊布利特是一种转复房颤快速、有效的药物。 Objective To assess the therapeutic efficacy and safety on paroxysmal atrial fibrillation with ibutilide versus amiodaron and propafenone.Methods 90 patients with paroxysmal atrial fibrillation were randomly divided into three groups.Group A was treated with ibutilide(1 mg,iv,n=30),group B was given amiodarone(150 mg,iv,n=30) and Group C was given propafenone(70 mg,iv,n=30).The study drugs were infused within 10 minutes in aids of ECG and blood pressure monitoring.The patient who remained AF after treatment repeated the prior infusion.The cardioversion rate and time,heart rate,QT interval,QRS interval and adverse effects within 1 h,2 h,4 h,24 h were recorded.Results The cardioversion rate and cardioversion time of group A was 83.33% and(24.3±10.7)min,respectively superior to those of the other groups.The adverse effects of group A was 3.33%,lower than that of the group C,while compared with group B,there was no significant statistic difference.The heart rates all decreased after treatment.The QT interval of group A was significantly prolonged compared with the other groups.There was no obvious change in group B.The QRS interval of group C was significantly prolonged compared with the other groups.The QRS intervals of group B and group C had no changes.Conclusion The efficacy of ibutilide in treating paroxysmal atrial fibrillation is superior to amiodarone and propafenone.The effect of ibutilide on heart rate and QT interval is more significant than amiodarone and propafenone,while it has no effect on QRS interval.Ibutilides is an effective and safe drug in atrial fibrillation cardioversion
作者 吕蒙
出处 《实用药物与临床》 CAS 2012年第11期739-741,共3页 Practical Pharmacy and Clinical Remedies
关键词 阵发房颤 伊布利特 胺碘酮 普罗帕酮 Paroxysmal atrial fibrillation Ibutilide Amiodarone Propafenone
  • 相关文献

参考文献10

  • 1Delle KG, Schillinger M, Geppert A, et al. Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population J. Wien Klin Wochenschr,2005,117 : 92- 97.
  • 2Caron MF, Kluger J, Tsikouris JP, et al. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibu- tilide[ J]. Pharmacotherapy,2003,23 : 296-301.
  • 3Fuster V, Ryden LE, Carnnom DS, et al. ACC/AHA/ESC 2006 guidelines for the management Patients with atrial fibril- lation, executive summary [ J ]. Circulation, 2006, 114 : 700- 752.
  • 4Oshikawa N, Watanabe I, Masaki R, et al. Frequency depend- ent electrophysiogical effect of ibutilide on human atrium and ventricle[ J]. J Interv Card Electrophysio1,200l ,5 ( l ) :81-87.
  • 5Gowdw RM, Punukollu G, Khan LA, et al. Ibutilide for phar- macological cardioversion of atrial fibrillation and flutter: im- pact of race on efficacy and safety[ J]. Am J Ther,2003,10 (4) :259-263.
  • 6Lip GY, Tello Montoliu A. Management of atrial fibrillation [J]. Heart,2006,92(8) :117-1182.
  • 7张楠,郭继鸿,张海澄,孙健玲,陈冰,游红.依布利特与普罗帕酮转复心房颤动的临床研究[J].中华心律失常学杂志,2005,9(1):29-33. 被引量:13
  • 8Nikolaos V, Kafkas, Sotirios P, et al. Conversion efficacy of in- travenous ibutilide compared with intravenous amiodarone in patients with recent onset atrial fibrillation and atrial flutter [J]. Int J Cardiol,2007,118(3) :321-325.
  • 9Emannuel EO, Schmid ER, Schmidlin D, et al. Ibutilide versus amiodarone in atrial fibrillation:A double-binded randomized study[ J]. Care Med,2003,31 : 1031-1034.
  • 10孙超,刘书旺,郭静萱.伊布利特与普罗帕酮转复心房颤动的疗效及电生理作用的差异[J].中国心脏起搏与心电生理杂志,2011,25(3):210-212. 被引量:13

二级参考文献30

  • 1张海澄,郭继鸿,方全,郑亚安,孙跃民,朱文青,万征,郭静萱,葛均波,韩少梅.静脉注射伊布利特与普罗帕酮转复心房颤动和扑动的多中心研究[J].中华医学杂志,2005,85(12):798-801. 被引量:43
  • 2Lych JR, Baskin EP, Nutt EM, et al. Comparision of binding to rapidly activating delayed rectifier K channel, Ikr and effects on myocardial refractoriness for class Ⅲ antiarrythmic agents[ J]. J Cardiovasc Pharmacol, 1995,25:336.
  • 3Naccarelh GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of ibutilide [ J ]. Am J Cardiol, 1996, 78 ( 8 A) : 12.
  • 4Baskin EP, Lynch JJ Jr. Differential atrial versus ventricular activities of class Ⅲ potassium channel blockers [J].J Phannacol Exp Ther, 1988,285( 1 ) :135.
  • 5Volgman AS, Carberry PA, Stambler BG, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainede in patients with atrial flutter and fibrillation[ J]. J Am Coll Cardial, 1998,31 : 1 414.
  • 6Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide over sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide-Sotalol Computer Study Group[J]. Heart, 1998,79:568.
  • 7Murray KT. Ibutilide [ J]. Circulation, 1998, 97:493.
  • 8Kowey PR, Vanderlugt JT, Lunderer JR. Safety and risk-benefit analysis of ibutilide for acute conversion of atrial fibrillation and flutter [J].Am J Cardiol, 1996,78:46.
  • 9Hen YJ, Hsieh MH, Chion CW, et al.Electropharmocologic characteristics of ventricular proarrythmia induced by ibutilide[J].J Cardivasc Pharmacol,1999,34(2) :237.
  • 10Naccarelli GV,Lee KS,Gibson JK,et al.Electrophysiology and pharmacology of ibutilide.Am J Cardiol,1996,78:12-16.

共引文献24

同被引文献63

  • 1Panagiotis Korantzopoulos,Konstantinos P Letsas,Anna Kotsia,Giannis Baltogiannis,Kallirroi Kalantzi,Konstantinos Kyrlas,John A Goudevenos.Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients[J].World Journal of Cardiology,2013,5(7):242-246. 被引量:3
  • 2Kalkas NV, Patsilinako~ SP, Merinos GA, et al. Conversion effica- cy of intravenous ibutilide compared with intravenous amiodarone in pa- tients with recent-onset atrial fthrillation and atrial flutter [J]. Int J Cardiol, 2007, 118 (3): 321.
  • 3Andrs RPR, Augusto HU, Cdso F, et al. Relationship among amioda- rone, new class Ⅲ antiarrhythmics, miscellaneous agents and acquired long QT syndrome [J]. Cardiol J, 2008, 15 (3) : 209-219.
  • 4Mountantonakis SE, Moutzouris DA, Tiu RV, et 8]. Ibutilide to expe- dite ED therapy for recent- onset atrial fibrillation flutter [J]. Am J E- merg Meal, 2006, 24 (4): 407-412.
  • 5Wilber D J, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial [J]. JAMA, 2010, 303(4): 333- 340.
  • 6Piceini J P, Lopes R D, Kong M H, et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of mrandomized, controlled trials[Jl. Circ Arrhythm Electrophysiol, 2009, 2(6): 626- 633.
  • 7Oral H, Chugh A, Good E, et al. Radiofrequency Catheter Ablation of Chronic Atrial Fibrillation Guided by Complex Elctrograms [J]. Circulation, 2007, 115(20) : 2606-2612.
  • 8Sanders P, Hocini M, Jais P, et al. Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial ill:dilation. Long-term clinical outcome [J]. Eur Heart J, 2007, 28(15): 1862-1871.
  • 9Asada-Kamiguchi J, Tabata T, Popovic Z B, et al. Non- invasive assessment of left ventricular relaxation during atrial filrillation using mitralflow propagation velocity [J]. Eur J Echocardiogr, 2009, 10(7) : 826-832.
  • 10Mntoki H, Koyama J, Tomita T, et al. Transient pseudorestrictive pattern of transmitral flow velocity curve in patients with paroxysmalatrial fibrillation [J]. Echocardiography,2011, 28(3) : 289-297.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部